AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29334491 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed
Number of subjects: 1085
Study 29334491 — intervention group
Group type: COMPARATOR
Intervention: OLM/HCTZ 20/12.5 mg once daily titrated to 40/25 mg if needed
Number of subjects: 1085
Study 29334491 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CTD lower dose
Number of subjects: 1085
Study 29334491 — intervention group
Group type: EXPERIMENTAL
Intervention: AZL-M/CTD higher dose
Number of subjects: 1085
Study 29334491 — intervention group
Group type: COMPARATOR
Intervention: OLM/HCTZ
Number of subjects: 1085
Study 29334907 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral tilting position after subarachnoid block (SAB)
Number of subjects: 105
Study 29334907 — intervention group
Group type: COMPARATOR
Intervention: Supine position after subarachnoid block (SAB)
Number of subjects: 105
Study 29334920 — intervention group
Group type: EXPERIMENTAL
Intervention: Study site for delivery
Number of subjects: 3243
Study 29334920 — intervention group
Group type: EXPERIMENTAL
Intervention: Study site for follow-up visits
Number of subjects: 3243
Study 29334920 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare facility for sick infants
Number of subjects: 3243
Study 29335013 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week YMCA community-based wellness program (FIT for FUNCTION)
Number of subjects: 216
Study 29335013 — intervention group
Group type: COMPARATOR
Intervention: Standard YMCA membership
Number of subjects: 216
Study 29335017 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopy (SPL)
Number of subjects: 0
Study 29335017 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 0
Study 29335020 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide SNP genotyping and gene expression profiling of lung tissue samples
Number of subjects: 117
Study 29335020 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative analysis using ensemble statistical and network methods
Number of subjects: 117
Study 29335020 — intervention group
Group type: EXPERIMENTAL
Intervention: Top gene identified from integrative analysis
Number of subjects: 117
Study 29335020 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes identified with RNA binding activity
Number of subjects: 117
Study 29335020 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene identified in network communities with validated disease relevance
Number of subjects: 117
Study 29335232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app
Number of subjects: 0
Study 29335232 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation app
Number of subjects: 0
Study 29335232 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no app)
Number of subjects: 0
Study 29335234 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mHealth platform with patient-held smartcard for storing test results of HIV, HBV, and SCD.
Number of subjects: 0
Study 29335291 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette Smoking
Number of subjects: 0
Study 29335291 — intervention group
Group type: COMPARATOR
Intervention: Single Conventional Cigarette
Number of subjects: 0
Study 29335333 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (initially pursued)
Number of subjects: 1866
Study 29335333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebleeding
Number of subjects: 1866
Study 29335333 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (discontinued after admission)
Number of subjects: 1866
Study 29335831 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-hospital transport (IHT) of ARDS patients
Number of subjects: 431
Study 29335831 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation treatment
Number of subjects: 431
Study 29335831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation during IHT
Number of subjects: 431
Study 29335831 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration and distance of IHT
Number of subjects: 431
Study 29335895 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 19
Study 29336016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 0
Study 29336179 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab therapy
Number of subjects: 0
Study 29336179 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipneumococcal vaccination
Number of subjects: 0
Study 29336228 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTI-30 therapeutic interventions
Number of subjects: 0
Study 29337030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal IL-25
Number of subjects: 0
Study 29338080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, gemcitabine, and veliparib (80 mg twice daily on days 1 to 12)
Number of subjects: 17
Study 29338080 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine (600 mg/m2 and 25 mg/m2 respectively)
Number of subjects: 17
Study 29338731 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthCorps program
Number of subjects: 611
Study 29338731 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 611
Study 29338758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (25, 10, or 2 μg of vitamin D3 per day)
Number of subjects: 85
Study 29338758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status at 6 years of age
Number of subjects: 85
Study 29338953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gun-related violent crime (1 per 10,000 people)
Number of subjects: 48
Study 29338953 — intervention group
Group type: EXPERIMENTAL
Intervention: Homicide rates
Number of subjects: 48
Study 29339012 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone communication
Number of subjects: 1395
Study 29339012 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination
Number of subjects: 1395
Study 29339012 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person communication
Number of subjects: 1395
Study 29339202 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished enamel samples exposed to orange juice for 5, 10, or 15 minutes in both in-vivo and ex-vivo conditions.
Number of subjects: 30
Study 29339202 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished enamel samples exposed to orange juice for 30 minutes in both in-vivo and ex-vivo conditions.
Number of subjects: 30
Study 29339269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m2)
Number of subjects: 99
Study 29339394 — intervention group
Group type: EXPERIMENTAL
Intervention: Finafloxacin; administered orally
Number of subjects: 127
Study 29339403 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine combined with chemotherapy
Number of subjects: 0
Study 29339691 — intervention group
Group type: EXPERIMENTAL
Intervention: Current clinical practice evaluation through a cross-sectional survey
Number of subjects: 2000
Study 29339691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional survey of public perception and knowledge of cholesterol treatment
Number of subjects: 2000
Study 29340875 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-based protocol (target 16-24 min of the R parameter)
Number of subjects: 42
Study 29340875 — intervention group
Group type: COMPARATOR
Intervention: aPTT-based protocol (target 1.5-2 of aPTT ratio)
Number of subjects: 42
Study 29340875 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-based protocol
Number of subjects: 42
Study 29340875 — intervention group
Group type: COMPARATOR
Intervention: aPTT-based protocol
Number of subjects: 42
Study 29340911 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of sexual violence (SV)
Number of subjects: 334
Study 29340911 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to sexual violence (SV)
Number of subjects: 334
Study 29341967 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO) at an initial dose of 10 (10, 15) ppm for adults, 20 (18, 20) ppm for children, and 17 (11, 20) ppm for neonates, administered for a median duration of 3.9 (1.9, 6.1) days for adults, 3.8 (1.8, 6.8) days for children, and 3.1 (1.0, 5.7) days for neonates.
Number of subjects: 236
Study 29342018 — intervention group
Group type: EXPERIMENTAL
Intervention: MILOS operation
Number of subjects: 615
Study 29342264 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 515
Study 29342267 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg of SLD-PQ
Number of subjects: 51
Study 29342267 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg of SLD-PQ
Number of subjects: 51
Study 29343131 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg
Number of subjects: 2370
Study 29343131 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg
Number of subjects: 2370
Study 29343156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based hypertension self-management support system
Number of subjects: 20
Study 29343167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically assisted hydration, mouth care and usual other care
Number of subjects: 200
Study 29343167 — intervention group
Group type: COMPARATOR
Intervention: Regular mouth care and usual other care
Number of subjects: 200
Study 29343266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29343297 — intervention group
Group type: EXPERIMENTAL
Intervention: Contegra®
Number of subjects: 82
Study 29343297 — intervention group
Group type: COMPARATOR
Intervention: Homograft
Number of subjects: 82
Study 29343297 — intervention group
Group type: EXPERIMENTAL
Intervention: Contegra® and Homograft
Number of subjects: 82
Study 29343534 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT and hs-cTnI
Number of subjects: 3828
Study 29343534 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 3828
Study 29343534 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 3828
Study 29343998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker respiratory disturbance index (RDI)
Number of subjects: 68
Study 29343998 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy
Number of subjects: 68
Study 29344432 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccine with Montanide as an adjuvant
Number of subjects: 4
Study 29344432 — intervention group
Group type: COMPARATOR
Intervention: Poly ICLC
Number of subjects: 4
Study 29344726 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks
Number of subjects: 1070
Study 29345044 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-063 at 0.3 mg/kg
Number of subjects: 0
Study 29345044 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-063
Number of subjects: 0
Study 29346367 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) administered orally
Number of subjects: 8
Study 29346377 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (MDA) delivered door-to-door, twice annually for three years.
Number of subjects: 80000
Study 29346377 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care MDA, typically annual school-based deworming.
Number of subjects: 80000
Study 29346377 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide MDA
Number of subjects: 80000
Study 29346388 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg ivermectin tablet
Number of subjects: 54
Study 29346388 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg ivermectin tablet
Number of subjects: 54
Study 29346388 — intervention group
Group type: COMPARATOR
Intervention: Standard weight-based regimen (150–200 μg/kg)
Number of subjects: 54
Study 29346478 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib (50 to 650 mg/d during dose-escalation; 100 mg/d during phase 1 expansion and phase 2)
Number of subjects: 281
Study 29346478 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib
Number of subjects: 281
Study 29346478 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids for management of IDH-DS
Number of subjects: 281
Study 29346519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 400 mg/m2 loading dose in week 1 followed by 250 mg/m2 weekly and cisplatin 30 mg/m2 concurrent with 6 weeks of intensity-modulated radiotherapy (60-66 Gy in 30 daily fractions)
Number of subjects: 46
Study 29346834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) 200 mg once daily plus ritonavir-boosted danoprevir (DNVr) 100 mg/100 mg twice daily and oral ribavirin (RBV) 1000/1200 mg/day for 12 weeks
Number of subjects: 38
Study 29346833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab in combination with Gefitinib
Number of subjects: 0
Study 29346833 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29347915 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported current insulin use
Number of subjects: 498
Study 29347915 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frequent non-severe hypoglycemia in the past year
Number of subjects: 498
Study 29347915 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported severe hypoglycemia in the past year
Number of subjects: 498
Study 29347915 — intervention group
Group type: EXPERIMENTAL
Intervention: Being very worried about hypoglycemia at least occasionally
Number of subjects: 498
Study 29347915 — intervention group
Group type: EXPERIMENTAL
Intervention: Being very worried about hypoglycemia at least occasionally (for family members)
Number of subjects: 498
Study 29347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions/week of knee-extensor strength exercise (three sets, 12 repetitions at 12 RM, per exercise session) for 12 weeks
Number of subjects: 140
Study 29347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions/week of knee-extensor strength exercise (three sets, 12 repetitions at 12 RM, per exercise session) for 12 weeks
Number of subjects: 140
Study 29347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Six sessions/week of knee-extensor strength exercise (three sets, 12 repetitions at 12 RM, per exercise session) for 12 weeks
Number of subjects: 140
Study 29347947 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 140
Study 29347952 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality collaborative interventions including interdisciplinary case analyses, external peer-reviews, hospital-wide staff education, and implementation of rapid response teams.
Number of subjects: 75
Study 29347952 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims data analysis and risk-adjusted hospital mortality reporting.
Number of subjects: 75
Study 29347952 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly quality reports focusing on risk-adjusted hospital mortality.
Number of subjects: 75
Study 29347983 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based support and coaching intervention for 8 weeks
Number of subjects: 16
Study 29347987 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biological parameters at ICU discharge including N-terminal pro-B type natriuretic peptide, high-sensitive troponin I, bioactive-adrenomedullin, and soluble-ST2.
Number of subjects: 1570
Study 29347987 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated biomarkers of cardiac and vascular failure at ICU discharge.
Number of subjects: 1570
Study 29347993 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal.
Number of subjects: 88
Study 29347991 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical exercise program using a rowing machine, three times a week for three months (experimental group)
Number of subjects: 42
Study 29347991 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study 29347991 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical exercise program
Number of subjects: 42
Study 29348128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat (PEV) 20 or 30 mg/m² combined with azacitidine (AZA)
Number of subjects: 0
Study 29348128 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29348179 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 29348179 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking status
Number of subjects: 0
Study 29349065 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 acids supplementation (2 g/day)
Number of subjects: 114
Study 29349065 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 114
Study 29349545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stents (BMS) with clopidogrel 75 mg for 4 weeks
Number of subjects: 765
Study 29349545 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES) without HTPR with clopidogrel for 6 months
Number of subjects: 765
Study 29349545 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES) with HTPR with clopidogrel for 6 months
Number of subjects: 765
Study 29349598 — intervention group
Group type: EXPERIMENTAL
Intervention: lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose followed by 420 mg in Cohorts 1 and 2; 420 mg without loading dose in Cohort 3) plus paclitaxel (80 mg/m2) every 3 weeks
Number of subjects: 35
Study 29350386 — intervention group
Group type: COMPARATOR
Intervention: VKAs (acenocoumarol, warfarin)
Number of subjects: 3528
Study 29350386 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 3528
Study 29350386 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3528
Study 29350386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of dabigatran and rivaroxaban
Number of subjects: 3528
Study 29350386 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 3528
Study 29350386 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (dabigatran and rivaroxaban)
Number of subjects: 3528
Study 29350463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 720 mg BID
Number of subjects: 6
Study 29350463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg BID
Number of subjects: 6
Study 29350586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise as a treatment for depression
Number of subjects: 0
Study 29350586 — intervention group
Group type: EXPERIMENTAL
Intervention: Media campaign
Number of subjects: 0
Study 29350586 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAD-UK trial results
Number of subjects: 0
Study 29351649 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in Fulani girls
Number of subjects: 98
Study 29351649 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in Fulani boys
Number of subjects: 98
Study 29351649 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in Wolof boys
Number of subjects: 98
Study 29351649 — intervention group
Group type: COMPARATOR
Intervention: Schistosoma haematobium infection prevalence
Number of subjects: 98
Study 29351667 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day benznidazole orally in two divided doses for 8 weeks
Number of subjects: 99
Study 29351822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (with OA and with OSA)
Number of subjects: 60
Study 29351822 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (Control)
Number of subjects: 60
Study 29351822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (without OA and with OSA)
Number of subjects: 60
Study 29351822 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (with OA and without OSA)
Number of subjects: 60
Study 29351897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care after OHCA
Number of subjects: 50
Study 29351900 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mental health interventions
Number of subjects: 18
Study 29351982 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemia survivors
Number of subjects: 1025
Study 29351982 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 1025
Study 29351986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (oral JAK1/2 inhibitor), at least six cycles administered to 9 patients (27.3%), more than six cycles to 6 patients (18.2%)
Number of subjects: 33
Study 29351986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (oral JAK1/2 inhibitor)
Number of subjects: 33
Study 29352057 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow Re-Direction Endoluminal Device (FRED)
Number of subjects: 103
Study 29352572 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 250mg combined with carboplatin AUC 4 and gemcitabine 800mg/m
Number of subjects: 75
Study 29352572 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib plus carboplatin/gemcitabine
Number of subjects: 75
Study 29352703 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy
Number of subjects: 52
Study 29352719 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy combinations (including bendamustine-containing regimens)
Number of subjects: 1494
Study 29352719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine-containing regimens
Number of subjects: 1494
Study 29352719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib or idelalisib in the relapse/refractory setting
Number of subjects: 1494
Study 29352719 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable-risk genetics, age ≥ 75 years, race, and treatment choice at enrollment
Number of subjects: 1494
Study 29352732 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 44
Study 29353109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus stopped at day +90
Number of subjects: 102
Study 29353109 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus stopped at day +60
Number of subjects: 102